Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 9, 2010, Pages 1110-1115

  Rifai, Kinan ^a   Bode Boeger, Stefanie M ^b   Martens Lobenhoffer, Jens ^b   Ernst, Thomas ^a   Kretschmer, Ulrich ^a   Hafer, Carsten ^a   Fliser, Danilo ^a   Manns, Michael Peter ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

ADMA; Arginine; Extracorporeal dialysis; Fractionated plasma separation and adsorption; Liver failure; Plasma albumin; Prometheus; SDMA

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ARTIFICIAL LIVER; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMORBIDITY; FEMALE; HEMODIALYSIS; HUMAN; LIVER FAILURE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ARGININE; FEMALE; HUMANS; LIVER FAILURE; LIVER, ARTIFICIAL; MALE; MIDDLE AGED;

EID: 77955530041     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.485322     Document Type: Article

References (43)

1. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-136.
2. Boger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl 2003;4:1-3.
3. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:609-615.
4. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM. A symmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25: 1414-1418.
5. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Marz W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53:273-283. (Pubitemid 46338272)
6. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-e59.
7. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
8. Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-1600.
9. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function a meta-analysis. Nephrol Dial Transplant 2006;21:2446-2451.
10. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997;1:65-73.
11. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, Van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003;22:17-22.
12. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003;38:1063-1064.
13. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, Rodrigo JM, Serra MA. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006;231:70-75.
14. Vizzutti F, Romanelli RG, Arena U, Rega L, Brogi M, Calabresi C, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 2007;37:509-515.
15. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007;45:62-71.
16. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006;58:159-178.
17. Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E, Kurt Y, et al. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007;25: 327-335.
18. Anderstam B, Katzarski K, Bergstrom J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997;8:1437-1442.
19. Schmidt RJ, Domico J, Samsell LS, Yokota S, Tracy TS, Sorkin MI, et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999;34:228-234.
20. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
21. Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC, et al. Low dialysance of asymmetric dimethylarginine (ADMA)-in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004;62:295-300.
22. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-2452.
23. Bergamini S, Vandelli L, Bellei E, Rota C, Manfredini P, Tomasi A, et al. Relationship of asymmetric dimethylarginine to haemodialysis hypotension. Nitric Oxide 2004;11: 273-278.
24. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-787.
25. Tsikas D, Beckmann B. Albumin from human serum does not contain asymmetric dimethylarginine (ADMA). Clin Biochem 2009;42:1739-1740.
26. Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, Hinz AV, DAlecy LG. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 2006;291: H1788-H1796.
27. Kielstein JT, Hesse G, Bahr MJ, Tsikas D, Terkamp C, Martens-Lobenhoffer J, et al. Procedure-related pulmonary hypertension in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection-role of ethanol, hemolysis, asymmetric dimethylarginine, and the nitric oxide system. Crit Care Med 2009;37:1483-1485.
28. Rifai K, Tetta C, Ronco C. Prometheus: from legend to the real liver support therapy. Int J Artif Organs 2007;30:858-863.
29. Rifai K, Ernst T, Kretschmer U, Hafer C, Haller H, Manns MP, Fliser D. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 2005;23:298-302.
30. Martens-Lobenhoffer J, Bode-Boger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-493.
31. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003;108:3042-3047.
32. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177. (Pubitemid 38114135)
33. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024-2029.
34. Jacobi J, Tsao PS. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 2008;28:224-237.
35. Vizzutti F, Romanelli RG, Arena U, Rega L, Brogi M, Calabresi C, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 2007;37:509-515.
36. Kielstein JT, Hesse G, Bahr MJ, Tsikas D, Terkamp C, Martens-Lobenhoffer J, et al. Procedure-related pulmonary hypertension in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection-role of ethanol, hemolysis, asymmetric dimethylarginine, and the nitric oxide system. Crit Care Med 2009;37:1483-1485.
37. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003;38:1063-1064.
38. Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PS, Robbins RC, Cooke JP. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005;112:1549-1556. (Pubitemid 41324515)
39. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007;18:1525-1533.
40. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23: 1455-1459.
41. Evenepoel P, Laleman W, Wilmer A, Claes K, Maes B, Kuypers D, et al. Detoxifying capacity and kinetics of Prometheus a new extracorporeal system for the treatment of liver failure. Blood Purif 2005;23:349-358.
42. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, et al. Prometheus a new extracorporeal system for the treatment of liver failure. J Hepatol 2003;39:984-990.
43. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004;27:143-147.